Red-Shifted Firefly Luciferase Optimized for Candida albicans In vivo Bioluminescence Imaging. by Dorsaz, S. et al.
ORIGINAL RESEARCH
published: 03 August 2017
doi: 10.3389/fmicb.2017.01478
Frontiers in Microbiology | www.frontiersin.org 1 August 2017 | Volume 8 | Article 1478
Edited by:
Ana Traven,
Monash University, Australia
Reviewed by:
Ilse Denise Jacobsen,
Leibniz-Institut für
Naturstoff-Forschung und
Infektionsbiologie–Hans Knöll Institut,
Germany
Eva Pericolini,
University of Modena and Reggio
Emilia, Italy
*Correspondence:
Dominique Sanglard
dominique.sanglard@chuv.ch
Specialty section:
This article was submitted to
Fungi and Their Interactions,
a section of the journal
Frontiers in Microbiology
Received: 28 June 2017
Accepted: 21 July 2017
Published: 03 August 2017
Citation:
Dorsaz S, Coste AT and Sanglard D
(2017) Red-Shifted Firefly Luciferase
Optimized for Candida albicans In vivo
Bioluminescence Imaging.
Front. Microbiol. 8:1478.
doi: 10.3389/fmicb.2017.01478
Red-Shifted Firefly Luciferase
Optimized for Candida albicans
In vivo Bioluminescence Imaging
Stephane Dorsaz, Alix T. Coste and Dominique Sanglard*
Institute of Microbiology, University of Lausanne, Lausanne, Switzerland
Candida albicans is a major fungal pathogen causing life-threatening diseases in
immuno-compromised patients. The efficacy of current drugs to combat C. albicans
infections is limited, as these infections have a 40–60% mortality rate. There is a
real need for novel therapeutic approaches, but such advances require a detailed
knowledge of C. albicans and its in vivo pathogenesis. Additionally, any novel antifungal
drugs against C. albicans infections will need to be tested for their in vivo efficacy
over time. Fungal pathogenesis and drug-mediated resolution studies can both be
evaluated using non-invasive in vivo imaging technologies. In the work presented here,
we used a codon-optimized firefly luciferase reporter system for detecting C. albicans
in mice. We adapted the firefly luciferase in order to improve its maximum emission
intensity in the red light range (600–700 nm) as well as to improve its thermostability
in mice. All non-invasive in vivo imaging of experimental animals was performed with
a multimodal imaging system able to detect luminescent reporters and capture both
reflectance and X-ray images. The modified firefly luciferase expressed in C. albicans
(Mut2) was found to significantly increase the sensitivity of bioluminescence imaging (BLI)
in systemic infections as compared to unmodified luciferase (Mut0). The same modified
bioluminescence reporter system was used in an oropharyngeal candidiasis model. In
both animal models, fungal loads could be correlated to the intensity of emitted light.
Antifungal treatment efficacies were also evaluated on the basis of BLI signal intensity.
In conclusion, BLI with a red-shifted firefly luciferase was found to be a powerful tool for
testing the fate of C. albicans in various mice infection models.
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INTRODUCTION
Fungal pathogens can cause a wide variety of diseases ranging from superficial infections to life-
threatening invasive infections. It is believed that invasive infections cause at least 1.5 million
deaths per year. Candida spp., and especially C. albicans, contribute to∼25% of all life-threatening
invasive diseases, despite antifungal treatments (Brown et al., 2012). These numbers highlight
the need to better understand how C. albicans infects its host, and to propose better therapeutic
alternatives.
Investigating C. albicans pathogenesis requires the use of animal infection models which
mimic the human host. The testing of alternative therapies to combat C. albicans infections also
necessitates these models. Classically, animal models of Candida infections use mammalian hosts
Dorsaz et al. C. albicans Red-Shifted Firefly Luciferase
(mice, rabbit, rat; Coste and Amorim-Vaz, 2015). The use of more
simple insect models such as Galleria mellonella has been also
undertaken (Amorim-Vaz et al., 2015).
Animal model infections face several challenges when
following the progression of a fungal infection. Fungal species
such as C. albicans propagate in different tissues over time. In the
case of an invasive infection performed by intravenous injection,
C. albicans reaches several organs (liver, spleen, kidneys) over
time and eventually accumulate in the kidneys (MacCallum
and Odds, 2005). In the case of oropharyngeal candidiasis
(OPC), superficial and underlying epithelial tissues are affected
without systemic spread of the fungus (Mosci et al., 2013;
Trautwein-Weidner et al., 2015). One other issue is the necessity
to evaluate the infection by determination of fungal burden,
which has traditionally involved euthanasia. After euthanasia,
specific tissues are chosen, homogenized, and plated onto
corresponding growth media to enumerate viable fungal cells.
Several alternatives to this labor-intensive classical procedure
have been proposed recently (Sturtevant, 2009; Zhang et al.,
2013), one of which allows the fate of fungal cells in living animals
to be followed in real time, using so called in vivo imaging (Brock,
2012).
In order to perform in vivo imaging, fungal cells need to
be recognized by imaging instruments. In the recent years,
bioluminescent imaging (BLI) has been the method of choice
for recording the presence of fungal elements in living tissues,
as it is an imaging modality that typically has excellent Signal
to Noise ratios (SNRs). It is widely known that bioluminescence
can be emitted by any one of several light production systems in
fungi. These include the Gaussia princep, the firefly and the click
beetle luciferases (Enjalbert et al., 2009; Jacobsen et al., 2014).
Each system uses codon-optimized gene and constitutive high
expression systems. G. princeps luciferase uses coelenterazine
as substrate and oxygen as co-factors to emit light, while the
click beetle and firefly luciferases use luciferin and ATP as co-
factors. Further, given that the G. princeps luciferase is naturally
a secreted protein, a modified version has been expressed so
that it will localize at the C. albicans cell wall through the
addition of a GPI-anchor (Enjalbert et al., 2009). In contrast,
firefly luciferase can only be an intracellular enzyme, since it
needs ATP produced by internal metabolic activity for light
emission. It is also widely recognized that in vivo BLI signals
scatter and tissue absorption is a function of bioluminescent
light spectral properties. While the emission peak of G. princeps
luciferase is at 480 nm, firefly luciferase has an emission peak
at around 560 nm. Additionally, two forms of click beetle
luciferase exist, one emitting in the green light at 537 nm
and one emitting in the red light at 613 nm. However, these
two luciferases are still only used in vitro (Kapitan et al.,
2016).
Given the above mentioned diversity of available fungal
luciferase systems, the selection of which luciferase option to
use for a given animal model is an important decision. Since
firefly luciferase has a light emission peak that extends toward
red light, it has a decisive advantage over G. princeps luciferase
light emission which is limited to blue light. In the context of
animal tissues, the range of light peak emission is important
since blue light is more absorbed by host tissues than is red-
shifted light. This phenomenon is clearly illustrated by two
studies that each uses a different luciferase (Enjalbert et al.,
2009; Jacobsen et al., 2014). First, in the study of Enjalbert et al.
(2009), C. albicans strains expressing GPI-anchored G. princeps
luciferase were used, and no satisfactory correlation was obtained
between the fungal burden and the light emitted following
mice systemic infection. In contrast, the C. albicans codon-
optimized firefly luciferase in a second study demonstrated a
good correlation between light emission and fungal burden in
systemic infection (Jacobsen et al., 2014). Firefly luciferase is,
therefore, considered to be the BLI reporter of choice when
following bioluminescent cells in infected mammals. In the
study of Jacobsen et al. (2014), the limit of luminescence
detection corresponded to about 3,000 cells per kidney, which
represents an already important amount of cells infecting the
tissues. It is known that firefly luciferase can be modified in
order to improve its spectral properties as well as enzymatic
and thermal stability properties. Such modifications have been
exploited to increase sensitivity of BLI in different type of
animal cells expressed in animal models. Until now, no further
improvement of firefly luciferase has been implemented in C.
albicans cells.
In this work, we undertook the modification of firefly
luciferase in order to improve the detection limits of C. albicans
cells in infected mice. We used here two different C. albicans
infectionmodels (systemic andOPC infections) and demonstrate
that the modified firefly luciferase performs better than the wild
type version. In addition, we used here a novel high sensitive
in vivo imaging system coupled with the specific needs of
containment of infected animals.
MATERIALS AND METHODS
Strains, Plasmids, and Growth Conditions
Escherichia coli DH5α was used as a host for plasmids
propagation. To grow DH5α, LB broth medium was used and
when necessary, supplemented with ampicillin (0.1 mg/ml).
Cultures of E. coli were incubated at 37◦C under constant
agitation (220 rpm) for 16–20 h. For plate cultures, 0.7%
BactoTM Agar (Brunschwig, Switzerland) was added.
C. albicans were grown in complete YEPD medium (1%
Bacto peptone [Difco Laboratories, Basel, Switzerland], 0.5%
yeast extract [Difco] and 2% glucose [Fluka, Buchs, Switzerland])
at 30◦C under constant agitation (220 rpm). For growth on
plates, 2% BactoTM Agar was added to the medium. Yeasts
were transformed by a lithium-acetate procedure with slight
modifications as previously described (Sanglard et al., 1996).
For the construction of the red-shifted luciferase, two rounds
of mutagenesis were performed by PCR. First, two mutations
(S284T and L295F) were introduced to allow peak emission red-
shifting. For this purpose, two overlapping PCR were performed
on pACT1-CaLucOpt (Jacobsen et al., 2014) using the Phusion R©
high-fidelity Taq polymerase (NEB, Switzerland). The first PCR
was carried out with the primers Hind_LUCopt (GCAAGCTTA
AAATGGAAGATGCTAAGAACA) and LUCopt_MUT1_R
(AAAGTAGATTTAGCCAAGAAAGAGAACAAAGTTGGA
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ACCAACAAAGCAGTTTGAATCTTG). The second PCR was
performed with primers LUCopt_MUT1_F (CAAGATTCA
AACTGCTTTGTTGGTTCCAACTTTGTTCTCTTTCTTGGC
TAAATCTACTTT) and Nhe-LUCopt (GCAAGCTAGCCT
ATACAGCAATTTTACCAC). The primers LUCopt_MUT1_F
and LUCopt_MUT1_R are overlapping and contained the
mutations. Next, a third PCR was performed to fuse the two
previous PCR products using 10 ng of each PCR product as
template and the two external primers (Hind_LUCopt and
Nhe-LUCopt). The final product was cloned after HindIII
and NheI digestion in pACT1-GFP (Barelle et al., 2004),
thus yielding pDS1901. A second round of mutagenesis was
performed to introduce two mutations (T214A and A215L).
The two PCR were performed on pDS1901. The first and
second PCR used, respectively, the primer pair Hind_LUCopt
and LUCopt_MUT2_R (GTGAGAGAATCTAACACACAA
AGCTCTGTGTGGCAAAGCAAC) and the primer pair
LUCopt_MUT2_F (GTTGCTTTGCCACACAGAGCTTTG
TGTGTTAGATTCTCTCAC) and Nhe-LUCopt. The primers
LUCopt_MUT1_F and LUCopt_MUT1_R are overlapping and
contained the mutations. A last PCR was performed as above
with primers Hind_LUCopt and Nhe-LUCopt and the final
product was cloned in pACT1-GFP to yield pDS1902.
The initial plasmids pACT1-CaLucOpt and pDS1902 were
digested by StuI and transformed as described above in CAF4-
2 (Fonzi and Irwin, 1993) to yield DSY4824 (expressing Mut0)
and DSY4823 (expressing Mut2), respectively. To express Mut2
in anotherC. albicans strain (strain 101, a gift from S. Leibundgut,
University of Zürich), a plasmid (pDS1928) containing the
SAT1 dominant marker was used (Reuss et al., 2004). pDS1928
was constructed from pDS1904, which contained the SAT1
resistance marker in CIp10 (Murad et al., 2000). A 3.5 kb XhoI-
BamHI fragment from pDS1902 containing Mut2 was inserted
in pDS1904 to yield pDS1928. This plasmid was linearized by
StuI for transformation into strain 101, yielding DSY4976. Five
clones of each transformation were checked for luminescence
signal and those with best signals were selected (data not
shown).
FIGURE 1 | Red shifting of firefly luciferase. (A) Schematic representation of mutations in firefly luciferase and their effects. (B) In vitro spectral analysis of luciferases.
C. albicans cells expressing Mut0 and Mut2 were grown to logarithmic phase and suspended in PBS as described in Material and Methods. Spectra were recorded
with a luminometer (upper graph) or with in-vivo Xtreme II (lower graph) and analyzed with Graph Prism. Dotted and full lines represent direct connections between
data points and data curve fitting, respectively. Gray zones represent data points not covered by the emission filters of the in-vivo Xtreme II instrument. Data were
obtained with triplicate cultures of C. albicans expressing each Mut0 or Mut2 (5 × 106 cells). (C) in vivo spectral analysis of luciferases. Mice infected with 5 × 105
cells were subjected to spectral analysis at 48 p.i. with in-vivo Xtreme II, and obtained data were analyzed with Graph Prism.
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In vitro Luciferase Assay
For in vitro cells suspension assays,C. albicans strains were grown
overnight in YEPD. Each strain was subsequently diluted 100-
fold in 3 ml of YEPD medium and grown to a concentration of
1.5 × 107 cells/ml. Cells were then washed twice in phosphate-
buffered saline (PBS: 137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 1.8 mM KH2PO4) and resuspended in 3 ml of PBS.
Cells concentration was measured using a spectrophotometer.
Cells were next centrifuged and resuspended in 2 × RPMI
(Sigma, Switzerland) buffered at pH 7 or 4.6 with MOPS at 108
cells/ml. Fifty microliters of the cells suspension were then loaded
on a 96-well plate (half-area, black, COSTAR). Sixty microliter
of D-luciferin (Biosynth, Switzerland) resuspended in H2O at a
concentration of 1.6 mg/ml was injected automatically into the
wells, followed by an orbital shacking of 3 s before recording
luciferase activity (RLU: Relative Luminescent Unit) using a
96-well plates luminometer (FLUOstar Omega, BMG Labtech).
Filters available for spectral analysis were at 460, 520, 530, 550,
580, 620, and 675 nm.
Mice Infection and Antifungal Therapy
All animal experiments were performed at the University
Hospital Center of Lausanne with approval through the
Institutional Animal Use Committee, Affaires Vétérinaires
du Canton de Vaud, Switzerland (authorization n◦ 1734.4),
according to decree 18 of the federal law on animal protection.
For all mice experiments, female BALB/c mice (7 weeks old;
Charles River France) were housed in ventilated cages with free
access to food and water. They were controlled and scored daily
for health status. Score of health was based on ability to heat
and drink, to move, on fur aspect, on body weight and on body
temperature (1 to 3 points for each criteria, where 1 corresponds
to “healthy” and 3 to “strongly altered”). Healthymice had a score
of 5 points. Mice with a score above 10 or with a body weight
loss equal or above 25% or body temperature below 35.5◦C
were immediately euthanized. The C. albicans strains were grown
in individual tubes for 16 h under agitation at 30◦C in YEPD
medium. Each strain was subsequently diluted 100-fold in YEPD
medium and grown overnight under agitation at 30◦C.Overnight
cultures were washed twice with PBS and resuspended in
5 ml PBS.
Systemic Infection
The concentration of each C. albicans culture was measured
through optical density, and each strain was diluted to 2 × 106
cells/ml. Mice were injected through the lateral tail vein with 250
µl of the cell suspension. For drug treatments, mice were injected
intraperitoneally daily starting 24 h post-infection (p.i.) with 100
µl of fluconazole (FLC: 10 mg/kg; Toronto Research Chemicals)
or 100 µl of caspofungin (CAS: 1 mg/kg; Cancidas R© Merck,
Switzerland). For determination of fungal burden, the kidneys
of euthanized animals were removed, homogenized in sterile
0.05% NP40 in water and serial dilutions were plated on YEPD
agar.
FIGURE 2 | Comparison of in vivo light emission from luciferases expressed in C. albicans. Luminescence signals obtained from mice kidneys infected with
C. albicans expressing either Mut0 or Mut2 were plotted against obtained CFU values. Corresponding X-ray and bioluminescence captures are shown at 48 h p.i.
(right panel) and highlight differences of luminescence between Mut0 and Mut2. Luminescence data are means of two kidneys ROI values from individual animals.
X-ray and luminescence overlay images of animals 1 and 2 correspond to data points plotted and indicated in the left panel.
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Oropharyngeal Infection
Immunocompetent mice were infected sublingually with 2.5 ×
106 CFU C. albicans yeast cells using a cotton ball as described
(Schönherr et al., 2017). For determination of fungal burden,
the tongue of euthanized animals was removed, homogenized
in sterile 0.05% NP40 in water and serial dilutions were plated
on YEPD agar. For drug treatment, FLC was diluted in 0.5%
hydroxyethyl-cellulose (Sigma) and 30 µl of the preparation was
administered under isoflurane anesthesia with 200 µl pipette tips
under the tongue daily starting 24 h p.i. (10 mg/kg/day).
In vivo Imaging and Quantification of
Bioluminescence
In vivo imaging was performed on a Bruker in-vivo Xtreme
II (Bruker BioSpin MRI GmbH, Ettlingen, Germany). In a
laminar flow biosafety cabinet, 5mice were generally anesthetized
with 3% isoflurane in an induction chamber, and then placed
in a Sealed Optical Imaging (OI) Tray, ventilated with 2.5%
isoflurane. Once the animals were correctly placed, the Sealed
OI Tray was disconnected from its anesthesia ventilation in
the biosafety cabinet, and immediately placed into the in-vivo
Xtreme II, where it was connected to 2.5% isoflurane ventilation.
Animal’s body temperature was managed by feedback regulated
controlled air flow and the set to 37◦C. BLI camera settings
were: field of view (FOV) of 19 × 19 cm, 8 × 8 binning and
5 min of exposure time. X-ray imaging camera settings were:
FOV of 19 × 19 cm and 5 s of exposure time. D-luciferin, a
substrate for firefly luciferase, was injected intraperitoneally (100
µL D-luciferin, at 18 mg/ml, Biosynth, Switzerland) 10 min
before luminescence imaging. The process of animal handling
and image acquisition is presented in a movie (Supplementary
Material). In addition to the intraperitoneal D-luciferin injection
in the OPC model, 10 µl of 1.5 mg/ml D-luciferin was
deposited under the tongue of the mouse prior to image
acquisition.
A region of interest (ROI) template of fixed size for each
kidney was used to ensure that areas of identical size were
measured in different animals. Background was measured for
each image and subtracted from the obtained signals. Value of
luminescence (photons/s/mm2) of a given animal corresponds to
the mean of the average luminescence of the two kidneys. ROI in
the OPC model correspond to the head region of mice.
For the spectral shift assay, different emission filters were
selected on the Bruker in-vivo Xtreme II machine at 535, 600,
700, 750, 790, and 830 nm, each with a bandpath of∼±20 nm.
RESULTS
Design of a Red-Shifted C. albicans
Optimized Firefly Luciferase
Taking advantages of a C. albicans codon-adapted firefly
luciferase (pACT1-CaLUCopt) reporter gene (Jacobsen et al.,
2014), an optimization of this luciferase was undertaken to
improve its properties. We were especially interested to improve
in vivo light emission and tissue penetrance. We first introduce
two mutations in CaLUCopt (S284T and L295F). S284T is
known to result in a red-shifting in light emission, while L295F
contributes to thermal stability (Branchini et al., 2005, 2007;
Figure 1A). The rationale behind this idea was to reduce light
absorption by tissues and hemoglobin, as reported (Papon et al.,
2014). In a second round of mutations, two other substitutions
were introduced (T214A and A215L) that were known to confer
enhancement of luciferin-dependent reactions and a better
resistance to body temperature as described (Branchini et al.,
2007).
C. albicans transformants with the original and the optimized
luciferase were obtained (designated as Mut0 and Mut2,
respectively) and their light emission spectra analyzed first
in vitro with whole cells on a standard laboratory luminometer
with seven emission filters covering a 460–675 nm range. Firefly
luciferase was detected in cell extracts from the C. albicans
transformants in similar amounts (Figure S1). As shown in
Figure 1B (upper panel), Mut0 showed a dual peak emission
profile with a major peak at around 500 nm. In contrast,
Mut2 exhibited a clear shift toward the red spectrum with a
FIGURE 3 | In vivo dose-response experiment and determination of the limit of
detection. (A) Dose response experiment was performed by injecting 104, 5 ×
104 or 105 and the luminescent signal was followed at 24-, 48-, and 72 h p.i.
(n = 6 mice /group). Background signal was subtracted from the individual
kidney signals. Corrected signals are represented in photon/s/mm2. Kidney
signals below background are plotted on the X-axis and were excluded for
statistical analysis (Mann-Whitney unpaired test, p-value: * < 0.05, ** < 0.01,
**** < 0.0001). (B) For each individual animal, the CFU/g measured from both
kidneys at 72 h p.i. is plotted against the average kidney luminescent signal.
The detection thresholds (50 CFU/pair of kidneys and 10 photons/s/mm2) are
indicated by the vertical and horizontal dashed regions, respectively. A linear
regression calculated on the detectable measures was performed and the R2
value is indicated. A dotted line indicates the detection limit of CFU based on
the detection threshold of luminescence.
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peak at about 625 nm. Similar in vitro measurements were
conducted using the Bruker in-vivo Xtreme II imaging platform,
containing five filters spanning from 520 to 850 nm. The
measured emission spectra profiles were similar to those obtained
with a luminometer, except that the major peak of Mut0
emission could not be recorded. This instrument is dedicated
to in vivo imaging and since wavelengths shorter than 550 nm
are absorbed by host tissues, it does not record light emitted
below 520 nm. Thus, it can be expected that Mut2 light emission
could be better captured by the instrument camera, while an
important portion of Mut0-emitted light may remain entrapped
by mammalian tissues and is not recorded by the instrument
dedicated to in vivo red-near infrared (NIR) imaging. In order
to assess this assumption, emission spectra were next measured
in vivo in mice infected with either C. albicans cells harboring
Mut0 or Mut2 (inoculum 5 × 105 CFU/mouse) at 48 h p.i..
This infection time allows the establishment of the C. albicans
infection at the site of the kidneys. After spectral analysis,
we could observe light emission peaks at higher wavelength
for Mut2 as compared to Mut0 (Figure 1C). In addition,
both luciferases displayed a peak emission shifted to higher
wavelengths as compared to in vitro emission (Figure 1B, lower
panel and Figure 1C), confirming that light in the green-blue
region is entrapped by mammalian tissues and not recorded, as
expected.
Comparison of Sensitivity of Both
Luciferases In vivo
We next addressed the performance of Mut2 in parallel to Mut0
in the invasive model of infection in mice. After acquisition
of total emitted bioluminescence in mice in the region of
the kidneys, fungal burdens in these organs were obtained
and were compared to the signals emitted by both luciferase
types (Figure 2). Signal intensities were about 3.7-fold higher
for Mut2 as compared to Mut0 (median of 828.9 and 3,089
photons/s/mm2, respectively; p < 0.005, Mann-Whitney test).
In addition, the Mut2 luminescent signal correlated better with
CFU than Mut0 (R2 0.92 vs. 0.58, Figure 2). These data clearly
establish Mut2 firefly luciferase as a more sensitive in vivo
luminescence reporter for C. albicans.
In vivo Dose Response Using the
Red-Shifted Firefly Luciferase
In this part of the study we aimed to establish the limit
of detection of Mut2 in vivo. For this purpose, mice were
infected with three different inoculums (104, 5 × 104, and 105
cells/mice) of C. albicans strain expressing Mut2. Infection was
monitored daily for three consecutive days recording kidney
luminescence emission (Figure 3A). Globally, kidney signals
were stable between 24- and 72 h p.i.. A dose response was visible
with a statistical significant difference betweenmice infected with
FIGURE 4 | Kinetics of mouse kidney infection. The average kidney luminescent signal, recorded at 6-, 18-, 24-, and 48 h p.i. (5 × 105 cells/mouse) is represented
and each mouse signal is connected overtime.
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104 cells as compared to mice infected with 105 cells at the three
time-points. The infection dose of 104 cells gave more variable
outcomes of infection (Figure 3A).
To establish the limit of detection, mice were sacrificed at 72
h p.i.. Fungal burdens were measured and correlated with the
corresponding previously recorded luminescent signals. Due to
technical limitations, it is not possible to detect<50 CFU per pair
of kidney. Luminescence signals above the background detection
levels were considered as bioluminescent signals produced by
C. albicans. Both thresholds are indicated in Figure 3B by
dashed regions. The detection limit should be set above the two
thresholds. Such limit was estimated at about 400 CFU/pair of
kidney (dotted line of Figure 3B), which corresponds to about
200 CFU/kidney.
Kinetics of Mice Systemic Infection
Kinetics of bioluminescence emission was addressed in infected
mice (n = 8) at early (6-, 18-, and 24 h) and later time points
(48- and 72 h). Light emission was originating mainly from
the region of the kidneys. While a constant progression of
emitted light was observed up to 24 h p.i. in almost all animals
(Figure 4), signals tended to stabilize at the later time points as
observed previously in Figure 3A, and dropped in one individual
(Figure 4, animal No 6). This observation suggests that fungal
loads increase dramatically in infected kidneys in the first 24 h
p.i., and stabilized thereafter. This is consistent with observations
made by Jacobsen et al. (2014), who suggested that fungal loads
were principally increasing over 24 h p.i.
In vivo Monitoring of Treatment Efficacy on
C. albicans Systematic Infection in Mice
BLI was next used to evaluate the efficacy of antifungal treatments
on C. albicans (Mut2) infections initiated by intravenous
challenge. We used fluconazole (FLC) and caspofungin (CAS)
as therapeutic agents in these experiments. Infected animal
treatments were started intraperitoneally 24 h after inoculation,
and then administrated daily. Animals were individually followed
by BLI for a period of 72–96 h p.i..
In the fluconazole experiment, the mean luminescence of
untreated control animals increased ∼2-fold over a 72 h
period of treatment (Figure 5A). In fluconazole-treated animals,
bioluminescence increased up to 48 h and then declined. These
data suggest a delay in fluconazole efficacy. Since fluconazole
was injected 24 h p.i., this delay may reflect limitations in the
pharmacokinetics of this antifungal agent. The fluconazole effect
observed with luminescent signals could be confirmedmeasuring
CFU at 72 h p.i. toward end of the experiment. While untreated
animals had a fungal burden around 104 CFU/g of kidney, treated
animals displayed 10- to 100 times lower kidney fungal burden
(Figure 5A, right panel).
The caspofungin treatment experiment was performed
separately and included an independent untreated control group.
Figure 5B indicates that bioluminescence signals of the untreated
group were first increasing over 72 h and then declined at 96 h
p.i.. In contrast, caspofungin-treated mice showed a decreasing
bioluminescence all along the entire treatment time course,
particularly from 48 to 96 h p.i.. Efficacy of caspofungin treatment
FIGURE 5 | In vivo dynamics of infection during drug treatment. Drug
treatment was initiated 24 h p.i. [intraperitoneal injection of fluconazole (FLC):
10 mg/kg (A), caspofungin (CAS): 1 mg/kg (B)] and repeated at 48 h p.i. for
FLC and 48 h p.i., and 96 h p.i. for CAS. (Mann-Whitney unpaired test,
p-value: * < 0.05, ** < 0.01, **** < 0.0001).
could be confirmed with fungal burden of kidneys in infected
animals at 96 h: while CFUs were slightly above the limit of
detection in treated animals (102/g kidneys), fungal burdens
were ranging between 105 and 107 CFUs/g kidney in untreated
animals. These experiments clearly highlight differences in the
pharmacodynamics of fluconazole and caspofungin treatments.
In vivo Monitoring of C. albicans OPC
Infection in Mice
The OPC model was also tested with bioluminescent C. albicans
cells expressing Mut2. To assess this model of infection with
a bioluminescence read-out, we used a persistent C. albicans
clinical isolate (strain 101). This strain is reported as persistent
in the OPC model of infection as opposed to the strain
SC5314, which is known to be cleared rapidly in this infection
model (Schönherr et al., 2017). In our hands, strain 101
can persist for at least 96 h in the OPC model (Figure 6B),
while SC5314 is cleared within 3 days p.i. (data not shown).
Infecting mice with the strain 101 expressing Mut2 in the
oropharyngeal area resulted as expected in luminescence signals
located in the head region (Figures 6A,B). We used several
experiments in which CFUs were obtained from animal’s tongues
at the end of experimentation (96 h) to correlate oral cavity
luminescent signal with tongue fungal burden. Figure 6A shows
that bioluminescence signals were correlated to recovered CFUs.
The correlation was significant, even though the correlation
coefficient (R = 0.52) was not excellent. We next addressed the
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FIGURE 6 | BLI in the C. albicans OPC model. (A) Correlation of BLI with CFUs of infected tongues. Data are originating from several independent infection
experiments with the C. albicans persistent isolate 101 expressing Mut2 (DSY4976). CFUs from homogenized tongues were taken at 96 h p.i.. In the right panel, BLI
from in-vivo Xtreme II (overlay of X-ray and bioluminescence capture) is shown to highlight the region of light emission. (B) FLC treatment of mice in the OPC model.
Data show bioluminescence signals obtained from untreated (Placebo, n = 6) and FLC-treated animals (n = 6). Mice were infected as described in Section Material
and Methods. FLC treatment was initiated at 24 p.i. with oral application of FLC (10 mg/kg) and repeated daily until sacrifice. In the right panel, BLI from in-vivo Xtreme
II (overlay of BLI on X-ray) is shown to highlight the location of light emission in untreated and treated animals. (Mann-Whitney unpaired test, p-value: * < 0.05, **** <
0.0001, NS, not significant).
efficacy of FLC in this model by applying the substance sublingual
at three different time points post infection (24-, 48-, and 72
h). While a significant decrease in light emission was detected
starting at 48 h post-treatment as compared to placebo, no light
was detected in FLC-treated at later time points (up to 96 h;
Figure 6B). In agreement, no C. albicans cells were recovered
from tongues of treated animals at 96 h post-treatment (data not
shown). These data clearly demonstrate the utility of BLI in this
type of infection model.
DISCUSSION
In this work, we designed a codon optimized luciferase with red-
shifted properties. Earlier work performed with firefly luciferase
adapted to mammalian expression identified a mutation (S284T)
causing a red-shift (Branchini et al., 2005). The introduction
of this mutation in the C. albicans codon-optimized luciferase
was accompanied by addition of other mutations described as
conferring thermal stability and enhanced light emitting activity
(L295F, T214A, and A215L). The resulting protein (Mut2)
expectedly produced efficient red-shifted light in vitro and
in vivo. We next attempted to modify the firefly luciferase Mut2
by other thermal stability mutations (I232A, I351V) and further
red-shifting (F465R) as previously described (Branchini et al.,
2010; see Figure 1A for details). However, the resulting proteins
did not confer better properties as compared to Mut2 at least in
vitro (data not shown). The introduction of these last mutations
in the codon-optimized firefly luciferase, and particularly in
Mut2, may result in improper folding and destabilization. As
published by Branchini et al. (2010), these effects need to
be compensated by the introduction of additional mutations.
Besides these protein modifications, it may be valuable in the
future to introduce into C. albicans the genes responsible for the
production of luciferin, which is the substrate of firefly luciferase.
This will avoid the need to inject luciferin repeatedly, andwill also
overcome any concerns regarding luciferin diffusion into infected
tissues. This has been achieved in mammalian cells which thus
became autonomous for light emission (Close et al., 2010).
BLI has been used already in C. albicans in different studies.
A codon-optimized firefly luciferase was first used in C. albicans
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and analyzed in vivo with systemic and vaginal infection model
(Doyle et al., 2006a,b). While the relationship between signal
intensity and CFUwas satisfactory in the vaginal infectionmodel,
the authors concluded that emitted signals were too low in the
invasive infection model and that there was a lack of correlation
between emitted light and fungal loads in this model (Doyle et al.,
2006a). Some of the signal detection issues of this study could
have been caused by first generation BLI equipments with poor
detection limits.
Later, firefly luciferase was also used by Jacobsen et al. (2014)
in C. albicans, however, light detection was performed with a
more recent instrumentation. In this study, Jacobsen et al. (2014)
successfully detected C. albicans bioluminescent signals and
established that this signal highly correlated with the fungal loads.
Authors estimated that the sensitivity of the codon optimized
firefly luciferase was adequate for visualization of the infection
(Jacobsen et al., 2014).
We thus attempted to compare the performance of BLI
in the present study with that published using the systemic
infection model and light detection in the region of the kidneys.
We estimated that a lower limit of detection for BLI (50
photon/s/mm2) corresponded to of about 200 CFU/kidney
with the instrumentation used here (in-vivo Xtreme II). Given
numbers published by Jacobsen et al. (2014) (100 photon/s/mm2
for 3,600 CFU/kidney), this suggests that the method used here
increases at least by 4- to 8-fold the sensitivity of C. albicans
detection. This performance can be attributed to several factors
including (i) the type of luciferase used (Mut2 has better tissue
penetration capacities than the wild type luciferase) and (ii)
technical differences provided by the luminescence acquisition
of instruments. This performance is even more remarkable when
taking in account that BLI data was collected here from animals
contained in Sealed OI Trays, which may create another obstacle
of emitted light to the high sensitivity camera.
We used BLI to establish two animal models of C. albicans
infection (systemic and OPC model). The systemic model
has been used by others, as mentioned above, with different
outcomes. The OPC model in immunocompromised mice was
used recently but with a Gaussia luciferase expressed at the
surface of C. albicans cells (Gabrielli et al., 2015). The use of
this luciferase system is possible for surface mucosal C. albicans
infection but is confronted by limitations in deeper tissue
infections due to poor penetration of blue emitted light from
the Gaussia luciferase. It is difficult to compare the performance
of the two systems since different equipments and image
acquisitions parameters were used. The Gaussia luciferase uses
coelenterazine as a substrate for light emission and this substance
is known to produce background luminescence in animals, thus
causing problems in data quantification especially at low fungal
burden (Vande Velde et al., 2013; Gabrielli et al., 2015). The
use here of the modified firefly luciferase (Mut2) offers an
attractive alternative to this model due to a low signal/noise
ratio.
In conclusion, we presented here an efficient and non-invasive
method to assess fungal burden in C. albicans infected animals.
This system takes advantage of a modified firefly luciferase and of
an efficient and sensitive image capture equipment, the in-vivo
Xtreme II. This system may be implemented in the future for
other fungal pathogens and animal models to study fungal-host
interactions.
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